Microglial Phagocytosis In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Microglial phagocytosis is the process by which [microglia[/entities/microglia/[diseases[/entities/microglia/[diseases[/entities/microglia/[diseases--TEMP--/entities/microglia)--FIX--, however, phagocytic function becomes profoundly dysregulated: [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--/entities/microglia" title="[Brown GC, Vilalta A, Bhatt D (2025]. Microglial phagocytosis in Alzheimer's Disease. Nature Reviews Neurology. DOI:10.1038/s41582-025-01162-yhttps://doi.org/10.1038/s41582-025-01162-y)">1 Link) (Brown et al., 2025.
Accumulating evidence indicates that dysregulated microglial phagocytosis is a central pathological mechanism in [Alzheimer's Disease (AD)[/diseases/[alzheimers-disease[/diseases/[alzheimers-disease[/diseases/[alzheimers-disease--TEMP--/diseases)--FIX--, with most known genetic risk loci — including [TREM2[/genes/[trem2[/genes/[trem2[/genes/[trem2--TEMP--/genes)--FIX--, CD33, [CR1[/genes/[cr1[/genes/[cr1[/genes/[cr1--TEMP--/genes)--FIX--, ABCA7, and PLCG2 — directly affecting phagocytic pathways [1]. Understanding the molecular switches that control beneficial versus detrimental phagocytosis is now considered critical for developing effective therapeutics for AD and other neurodegenerative conditions (Mediated et al., 2025.
[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX-- express a diverse repertoire of phagocytic receptors that recognize distinct ligands on their targets. These receptor systems work in concert to determine what gets engulfed and when [1] Link:
[TREM2[/genes/[trem2[/genes/[trem2[/genes/[trem2--TEMP--/genes)--FIX-- ([Triggering Receptor Expressed on Myeloid Cells 2] is the most important genetic determinant of microglial phagocytic capacity in neurodegeneration. [TREM2[/genes/[trem2[/genes/[trem2[/genes/[trem2--TEMP--/genes)--FIX-- binds to phosphatidylserine exposed on damaged [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, lipoproteins associated with [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- aggregates, and [APOE[/genes/[apoe[/genes/[apoe[/genes/[apoe--TEMP--/genes)--FIX-- link[1]:
In [AD], microglial phagocytosis is dysregulated at multiple levels [1] Link):
In [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--
Equally important is preventing harmful phagocytic activity:
Genome-wide association studies (GWAS) have revealed that the majority of AD genetic risk can be mapped to microglial phagocytic pathways [1]:
| Gene | Phagocytic Role | AD Risk Mechanism |
|---|---|---|
| [TREM2[/genes/[trem2[/genes/[trem2[/genes/[trem2--TEMP--/genes)--FIX-- | Phagocytic receptor | R47H reduces [Aβ[/entities/[Amyloid-Beta[/entities/[Amyloid-Beta[/entities/[Amyloid-Beta[/entities//entities/Amyloid-Beta clearance |
| CD33 | Phagocytic inhibitor | Common allele suppresses phagocytosis |
| CR1 | Complement receptor | Modulates C3b-dependent engulfment |
| ABCA7 | Lipid transporter | Impairs phagocytic membrane dynamics |
| PLCG2 | Signaling enzyme | Hypermorphic variant enhances phagocytosis (protective) |
| [BIN1[/genes/[bin1[/genes/[bin1[/genes/[bin1--TEMP--/genes)--FIX-- | Endocytic adaptor | Affects phagocytic internalization |
| CD2AP | Endocytic scaffold | Modulates phagocytic receptor trafficking |
| [APOE/[mTOR[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration--TEMP--/mechanisms)--FIX-- is essential for this metabolic switch; its failure in [TREM2[/entities/[trem2[/entities/[trem2[/entities/[trem2--TEMP--/entities)--FIX---variant [microglia[/entities/[microglia[/entities/[microglia[/entities/[microglia--TEMP--/entities)--FIX-- may underlie their phagocytic deficiency <a href="#references" class="ref-link" data-ref-number="2" data-ref-text="[Griciuc A, et al. (2022]. TREM2 dependent and independent functions of microglia in Alzheimer's Disease. Molecular Neurodegeneration, 17:84. DOI |
The study of Microglial Phagocytosis In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 8 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 34%